Elevance Health (ELV – Research Report) received a Buy rating and a $485.00 price target from Cantor Fitzgerald analyst Sarah James yesterday.

In a report released today, David S Macdonald from Truist Financial reiterated a Buy rating on Elevance Health (ELV – Research Report), with a ...

Ballentine Partners LLC lessened its holdings in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 26.5% during the ...

Elevance Health delivered earnings and 2025 guidance that broadly met analysts’ expectations, likely providing some relief to investors after a challenging quarter. The fourth-quarter results marked t ...

Health-care companies rose sharply amid strong earnings.

Mark Kaye, the chief financial officer, said the company took a "very disciplined approach between competitiveness and underwriting." ...

Elevance Health's quarterly dividend has been increased by 5% to $1.71 per share. The company's president and CEO, Gail K. Boudreaux, expressed the commitment to simplifying the healthcare experience ...

Elevance Health Inc. (ELV) on Thursday reported fourth-quarter net income of $418 million. The Indianapolis-based company said it had net income of $1.

It’s famous for caffeine, of course, but it also comes with some impressive health benefits. Americans love the dark brew: More than two-thirds, 67%, report drinking coffee in the past day ...

Elevance Health, Inc. (NYSE:ELV) received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$520 at one point, and dropping to the lows of ...

Elevance Health, Inc. has a fifty-two week low of $362.21 and a fifty-two week high of $567.26. The business has a 50-day moving average of $394.43 and a 200-day moving average of $477.48.

The Department of Health (DOH) on Friday dismissed reports of an alleged "international health concern" making the rounds on social media. “Kasalukuyang hindi sinusuportahan ng mga maaasahang ...